## Vensica Medical Secures $11 Million to Advance Needle-Free Treatment for Overactive Bladder
Vensica Medical, a pioneering company in urology therapeutics, has announced a significant milestone: the successful closing of an $11 million funding round. This investment will fuel the company’s upcoming Phase 2 clinical trials for its innovative treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin®) delivered through a proprietary, needle-free device.
The funding round was spearheaded by the Israel Biotech Fund (IBF) and joined by key strategic partners, Merz, a global leader in neurotoxins, and Laborie, a prominent player in urology medical devices. This strategic alliance reflects the collective belief in Vensica’s vision of transforming the standard of care for OAB by offering a minimally invasive, simple, and effective solution for patients.
Vensica’s revolutionary technology utilizes a needle-free drug delivery system that administers Xeomin® directly to the bladder wall. This approach is expected to provide patients with a less invasive and more comfortable treatment option compared to traditional injections. This could potentially revolutionize the treatment landscape for OAB.
Vensica’s ambition extends beyond OAB, with its needle-free drug delivery system designed to serve as a urology treatment platform for other bladder indications. This signifies their commitment to delivering a wider range of innovative solutions for urological conditions.
“We are incredibly excited to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment,” said Avner Geva, CEO of Vensica. “This funding allows us to move forward with Phase 2 trials and take a crucial step closer to bringing this innovative therapy to the patients who need it.”
As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic applications within various urological indications. This collaboration also includes valuable clinical development support from Merz, further solidifying their commitment to advancing next-generation urology treatments.
Vensica’s dedication to improving the lives of those suffering from OAB and other urological conditions is evident through its focus on developing innovative, minimally invasive therapies. The company’s commitment to clinical research and its strategic partnerships with industry leaders highlight their commitment to delivering groundbreaking solutions within the urology space.
For more information on Vensica and its upcoming clinical trials, please visit their website: https://vensica.com/